Statute Details
- Title: Health Products (Clinical Research Materials) Regulations 2016
- Act Code: HPA2007-S332-2016
- Type: Subsidiary Legislation (sl)
- Enacting Authority: Health Sciences Authority (HSA), with Minister for Health approval
- Authorising Act: Health Products Act (Cap. 122D), sections 71 and 72
- Commencement: 1 November 2016
- Current Version: Current version as at 27 Mar 2026
- Parts: Part 1 (General); Part 2 (Exceptions); Part 3 (Manufacture and Import); Part 4 (Supplies); Part 5 (Duties); Part 6 (Miscellaneous)
- Key Definitions (Section 2): “clinical research”, “clinical research material”, “auxiliary CRM”, “institutional review board”, “CTGT product”, “CTGTP Regulations”, and related terms
- Notable Provisions (by topic): import/export notifications and approvals; supply restrictions; labelling; traceability; record-keeping; adverse reaction reporting; defect reporting; recall; certificates; enforcement and offences
What Is This Legislation About?
The Health Products (Clinical Research Materials) Regulations 2016 (“CRMR”) set out a regulatory framework for how “clinical research materials” may be manufactured, imported, supplied, used, tracked, and reported on when they are intended for use in clinical research involving human subjects in Singapore. In plain terms, the Regulations aim to ensure that materials used in clinical studies—such as therapeutic products, placebos, and certain cell, tissue or gene therapy products—are handled safely and responsibly from the point they enter the supply chain through to their use and disposal in research.
The Regulations sit under the Health Products Act and operate alongside other Singapore research and healthcare regulatory regimes. They create targeted exceptions and obligations that recognise the special context of clinical research (including protocols, subject safety monitoring, and ethics oversight), while still applying core principles of product quality, accountability, and traceability.
For practitioners, the key practical takeaway is that the CRMR do not merely regulate “clinical trials” in the abstract. They regulate the materials used in clinical research—covering import and supply controls, labelling requirements, record-keeping, pharmacovigilance-style reporting, and recall duties. This makes the Regulations highly relevant to sponsors, manufacturers, importers, distributors, and healthcare institutions that handle research materials.
What Are the Key Provisions?
1. Core definitions and scope (Part 1, Section 2). The Regulations define “clinical research” and, crucially, “clinical research material”. A “clinical research material” is any therapeutic product, placebo, or specified CTGT product (cell, tissue or gene therapy product) that is manufactured, imported, or supplied for the purpose of being used in clinical research by way of administration to a subject in accordance with the protocol. The definition also captures CTGT products treated under the CTGTP Regulations (and whether certain notices have been submitted), and it includes “auxiliary CRM” (materials used for research needs but not the tested/reference material).
The definition of “administer” is broad: it includes oral administration, injection or other introduction into the body, and external application (with or without direct contact). This breadth matters because it can bring a wide range of research materials within the Regulations—even where the material is not a conventional medicine.
2. Exceptions and regulatory gateways for manufacture, import and supply (Part 2). Part 2 addresses when clinical research materials are exempted from the general requirements of the Health Products Act, and what conditions must be satisfied to rely on those exceptions. It includes:
- Notification of import (Section 4): importers must notify the Authority regarding imported clinical research materials.
- Approval for import of consignments containing psychotropic substances (Section 5): where consignments include psychotropic substances, prior approval is required.
- Approval for export of certain clinical research materials (Section 6): export of specified materials requires approval.
- Notification of supply by manufacturer (Section 7): manufacturers must notify the Authority when supplying clinical research materials.
These provisions create a compliance “front door” for cross-border movement and initial supply. For sponsors and logistics teams, the practical implication is that import/export activities cannot be treated as purely operational; they require regulatory steps and timing.
3. Manufacture and import controls (Part 3, Section 8). Part 3 provides the rules for manufacturing and importing clinical research materials. While the extract provided does not reproduce the full text of Section 8, the structure indicates that the Regulations impose conditions on who may manufacture/import and under what standards or authorisation arrangements. In practice, this typically aligns with quality assurance expectations and may require that manufacturing/import activities meet specified regulatory requirements.
4. Supply restrictions and labelling (Part 4). Part 4 governs how clinical research materials may be supplied. The Regulations include:
- Supply only as clinical research material (Section 9): materials must be supplied for the clinical research purpose contemplated by the protocol.
- Supply to subjects of prescription-only or pharmacy-only medicines (Sections 11 and 12): these provisions regulate the circumstances in which prescription-only or pharmacy-only medicines may be supplied to research subjects, including where supply occurs by administration of such medicines.
- Supply properly labelled (Section 13): clinical research materials must be properly labelled. Labelling is a critical compliance point because it supports safe administration, subject understanding (where applicable), and traceability.
For legal teams, these sections are important because they constrain “off-protocol” use and require that supply arrangements reflect the regulatory classification of the underlying product (e.g., prescription-only vs pharmacy-only) and the research context.
5. Duties relating to use, traceability, records, and reporting (Part 5). Part 5 is the operational backbone of the Regulations. It contains three divisions:
- Division 1 (Use and disposal; traceability): Section 14 requires proper “dealing” with clinical research materials. Section 14A imposes a duty to maintain a system of traceability for a CTGT product. This is particularly significant for advanced therapies where tracking chain-of-custody and product identity is essential for safety and accountability.
- Division 2 (Keeping of records): Sections 15 to 18 require records of manufacture, receipt and supply, and dealings with clinical research materials, including requirements on the production of records and the time for keeping them. Record-keeping is not optional; it is a compliance obligation that supports audits, investigations, and regulatory oversight.
- Division 3 (Reports to Authority): Section 19 requires notification of unexpected serious adverse drug reactions. Section 19A imposes a duty to report defects. Section 20 provides for recall of clinical research materials.
These provisions mirror key pharmacovigilance and quality defect management concepts, adapted to the clinical research setting. They also create legal duties that may overlap with sponsor obligations under ethics and trial governance, but the CRMR impose a direct regulatory reporting and recall framework.
6. Certificates, enforcement, and offences (Part 6). Part 6 includes:
- Certificates of manufacturing and distribution standards (Sections 21 and 22): these provisions require certificates demonstrating compliance with manufacturing/distribution standards for clinical research materials.
- Enforcement requirements (Section 23): this section sets out how enforcement is carried out.
- Offences (Section 24): it creates offence provisions for breaches of the Regulations. For practitioners, this is a reminder that non-compliance can carry criminal or regulatory consequences, not merely administrative inconvenience.
How Is This Legislation Structured?
The CRMR are organised into six parts:
- Part 1 (General): citation/commencement and definitions (Section 2).
- Part 2 (Exceptions): exceptions from the Health Products Act for manufacture, import and supply of clinical research materials, plus notifications/approvals for cross-border movements and manufacturer supply.
- Part 3 (Manufacture and Import): rules governing manufacture and import of clinical research materials.
- Part 4 (Supplies): restrictions on how clinical research materials may be supplied, including labelling and rules for prescription-only/pharmacy-only medicines.
- Part 5 (Duties): dealing with materials, traceability (notably for CTGT products), record-keeping, and reporting to the Authority (adverse reactions, defects, recall).
- Part 6 (Miscellaneous): certificates, enforcement requirements, and offences.
Additionally, the Regulations refer to schedules (Second and Third Schedules) which may contain further details relevant to compliance, classification, or procedural matters (not reproduced in the extract).
Who Does This Legislation Apply To?
The CRMR apply to persons who manufacture, import, supply, or otherwise “deal with” clinical research materials for use in clinical research by administration to human subjects in Singapore. This typically includes sponsors, manufacturers, importers, distributors, and healthcare service providers or institutions that handle research materials under protocols.
Because the Regulations impose duties on traceability systems (especially for CTGT products), record-keeping, adverse reaction reporting, defect reporting, and recall, the practical compliance perimeter extends beyond the sponsor to operational actors in the supply chain and clinical sites. Where a healthcare service licensee is involved, the Regulations’ definitions also link to the Healthcare Services Act 2020 (for concepts such as “permanent premises” and “business name”).
Why Is This Legislation Important?
The CRMR are important because they translate clinical research governance into enforceable product-handling obligations. Clinical research often involves complex logistics, multiple parties, and time-sensitive administration to subjects. The Regulations ensure that, even in a research context, materials are traceable, properly labelled, and subject to quality and safety reporting.
From an enforcement and risk-management perspective, Part 5 is the most consequential. Unexpected serious adverse drug reaction reporting (Section 19), defect reporting (Section 19A), and recall (Section 20) create legal duties that can affect trial continuity, subject safety, and regulatory scrutiny. Record-keeping duties (Sections 15–18) also matter because they provide the evidentiary basis for demonstrating compliance during inspections or investigations.
For practitioners advising sponsors or institutions, the Regulations also help clarify how to structure compliance workflows: import notifications and approvals must be planned; supply must be limited to the research purpose and supported by proper labelling; and traceability systems must be maintained, particularly for CTGT products. In short, the CRMR provide the compliance “spine” for legal defensibility in clinical research involving regulated health products.
Related Legislation
- Health Products Act (Cap. 122D)
- Healthcare Services Act 2020
- Human Biomedical Research Act 2015
- Health Products (Cell, Tissue and Gene Therapy Products) Regulations 2021 (CTGTP Regulations)
- Medical Registration Act 1997
- Dental Registration Act 1999
Source Documents
This article provides an overview of the Health Products (Clinical Research Materials) Regulations 2016 for legal research and educational purposes. It does not constitute legal advice. Readers should consult the official text for authoritative provisions.